(Q37760427)

22 August 2017

1 reference

title

Cystic fibrosis-related diabetes in children--gaps in the evidence? (English)

1 reference

22 August 2017

0 references

2

Craig F Munns

1 reference

22 August 2017

Malay Rana

1

1 reference

22 August 2017

Hiran Selvadurai

series ordinal

3

1 reference

22 August 2017

Kim C Donaghue

series ordinal

4

1 reference

22 August 2017

Maria E Craig

series ordinal

5

1 reference

22 August 2017

publication date

25 May 2010

1 reference

Nature Reviews Endocrinology

22 August 2017

published in

1 reference

22 August 2017

volume

6

1 reference

22 August 2017

issue

7

1 reference

22 August 2017

page(s)

371-378

1 reference

Glucose tolerance in patients with cystic fibrosis: five year prospective study

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Elevated gluconeogenesis and lack of suppression by insulin contribute to cystic fibrosis-related diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Management of cystic fibrosis-related diabetes in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Diabetes in cystic fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Demographics of glucose metabolism in cystic fibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Genetic determinants and epidemiology of cystic fibrosis-related diabetes: results from a British cohort of children and adults.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Epidemiology of cystic fibrosis-related diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Genetic determination of diabetes mellitus in patients with cystic fibrosis. Multicenter Cystic Fibrosis Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Beta-cell autoantibodies and diabetes mellitus family history in cystic fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Relative increase in IgG antibodies to Pseudomonas aeruginosa 60-kDa GroEL in prediabetic patients with cystic fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Cloning and nucleotide sequence comparison of thegroEoperon ofPseudomonas aeruginosaandBurkholderia cepacia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

NOD mouse diabetes: the ubiquitous mouse hsp60 is a beta-cell target antigen of autoimmune T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Antibodies to human HSP60 in patients with juvenile chronic arthritis, diabetes mellitus, and cystic fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Is cystic fibrosis-related diabetes an apoptotic consequence of ER stress in pancreatic cells?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Cystic fibrosis-related diabetes: the role of peripheral insulin resistance and beta-cell dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Pancreatic endocrine function in cystic fibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Insulin sensitivity and metabolic clearance rate of insulin in cystic fibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Enhanced glucose absorption in the jejunum of patients with cystic fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Management of cystic fibrosis related diabetes: a survey of UK cystic fibrosis centers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Identification and treatment of cystic fibrosis-related diabetes. A survey of current medical practice in the U.S.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Conventional measures underestimate glycaemia in cystic fibrosis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Clinical improvement in cystic fibrosis with early insulin treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Continuous glucose monitoring in cystic fibrosis patients according to the glucose tolerance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Microvascular complications in cystic fibrosis-related diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Low glycemic index breakfasts and reduced food intake in preadolescent children.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Long-term effect of insulin treatment in cystic fibrosis-related diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Use of the insulin pump in treat cystic fibrosis related diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Diabetes mellitus and cystic fibrosis: comparison of clinical parameters in patients treated with insulin versus oral glucose-lowering agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.85

Understanding cystic-fibrosis-related diabetes: best thought of as insulin deficiency?

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20498678

12 December 2020

inferred from PubMed ID database lookup

[Lung transplantation and the development of diabetes mellitus in adult patients with cystic fibrosis]

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20498678

12 December 2020

inferred from PubMed ID database lookup

Cloning and nucleotide sequence comparison of the groE operon of Pseudomonas aeruginosa and Burkholderia cepacia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20498678

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/NRENDO.2010.85

1 reference

release_xlbnv6gt6fehhcuet3lzwxureu

22 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xlbnv6gt6fehhcuet3lzwxureu

24 November 2022

mapped directly with Wikidata item

1 reference